<DOC>
	<DOC>NCT01466361</DOC>
	<brief_summary>This study is designed to evaluate the ability of a nicotine lozenge to relieve craving for a cigarette compared to a matched placebo (a placebo is like sugar pill and contains no active).</brief_summary>
	<brief_title>Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving</brief_title>
	<detailed_description />
	<mesh_term>Nicotine</mesh_term>
	<criteria>Generally healthy smokers who smoke more than 5 cigarettes per day Body mass index (BMI) within the range 1935 kilogram (kg)/meter (m)^2 Females of childbearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception. Women who are pregnant or who have a positive urine pregnancy test. Participants with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients. Clinical Study/Experimental Medication: Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit. Prior Concomitant Medication: Treatment with enzyme altering agents (e.g. carbamazepine, phenytoin, cimetidine, sodium valporate) within 30 days of the craving provocation visit; Use of any prescription psychoactive medication (such as but not limited to antidepressants, antipsychotics, anxiolytics) within 14 days of the craving provocation visit; Participant has used an overthecounter (OTC) medication such as antihistamines, sedating agents, or any compound that would have a sedating effect within 24 hours of the craving provocation visit; Current use of any nicotine replacement therapy. Substance abuse: Recent history or current history (within the last 1 year) of alcohol or other substance abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Nicotine</keyword>
	<keyword>Nicotine craving</keyword>
</DOC>